Retrieve available abstracts of 117 articles: HTML format
Single Articles
April 2025
UNTERRAINER LM, De Leiris N, Unterrainer M, Delker A, et al Evidence-Based Clinical Protocols to Monitor Efficacy of [(177)Lu]Lu-PSMA
Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer
Using Real-World Data.
J Nucl Med. 2025 Apr 24:jnumed.124.269431. doi: 10.2967/jnumed.124.269431. PubMedAbstract available
DE OLIVEIRA TAVEIRA M, Razmaria AA, Schoder H, Yeh R, et al Prostate Cancer Recurrence Due to Isolated Testicular Metastases Detected by PSMA
PET/CT.
J Nucl Med. 2025 Apr 10:jnumed.124.269361. doi: 10.2967/jnumed.124.269361. PubMedAbstract available
March 2025
YANG H, Wang J, Wen X, Guo H, et al Dansylated Amino Acid-Modified Long-Acting PSMA Derivatives
(68)Ga/(177)Lu-LNC1011 as Prostate Cancer Theranostics.
J Nucl Med. 2025 Mar 20:jnumed.124.268959. doi: 10.2967/jnumed.124.268959. PubMedAbstract available
TANG W, Qi L, Chen M, Zhang Y, et al Additive Value of [(68)Ga]Ga-RM26 PET/CT to [(68)Ga]Ga-PSMA-617 PET/CT in
Detecting Pelvic Lymph Node Metastasis in Prostate Cancer: A Prospective,
Single-Center, Phase II Study.
J Nucl Med. 2025 Mar 20:jnumed.124.269189. doi: 10.2967/jnumed.124.269189. PubMedAbstract available
BERNER K, Hernes E, Kvassheim M, Revheim ME, et al First-in-Human Phase 0 Study of AB001, a Prostate-Specific Membrane
Antigen-Targeted (212)Pb Radioligand, in Patients with Metastatic
Castration-Resistant Prostate Cancer.
J Nucl Med. 2025 Mar 13:jnumed.124.269299. doi: 10.2967/jnumed.124.269299. PubMedAbstract available
JEWELL KE, Buteau JP, Medhurst E, Kwan EM, et al Safety and Efficacy of 20 Cycles of [(177)Lu]Lu-PSMA-617 for Metastatic
Castration-Resistant Prostate Cancer.
J Nucl Med. 2025 Mar 13:jnumed.124.269447. doi: 10.2967/jnumed.124.269447. PubMed
FOXTON C, Waldron B, Veggerby Gronlund R, Simon JJ, et al Preclinical Evaluation of (177)Lu-rhPSMA-10.1, a Radiopharmaceutical for Prostate
Cancer: Biodistribution and Therapeutic Efficacy.
J Nucl Med. 2025 Mar 6:jnumed.124.268508. doi: 10.2967/jnumed.124.268508. PubMedAbstract available
JOHNSTONE CN, Osellame LD, Cao Z, McDonald AF, et al DNA-Dependent Protein Kinase Inhibitor Peposertib Enhances Efficacy of
(177)Lu-Based Radioimmunotherapy in Preclinical Models of Prostate and Renal Cell
Carcinoma.
J Nucl Med. 2025;66:385-390. PubMedAbstract available
February 2025
TURCO F, Gillessen S, Herrmann K, Paone G, et al Treatment Landscape of Prostate Cancer in the Era of PSMA Radiopharmaceutical
Therapy.
J Nucl Med. 2025 Feb 27:jnumed.124.267730. doi: 10.2967/jnumed.124.267730. PubMedAbstract available
EIFER M, Sutherland DEK, Goncalves I, Buteau JP, et al Therapy-Related Myeloid Neoplasms After [(177)Lu]Lu-PSMA Therapy in Patients with
Metastatic Castration-Resistant Prostate Cancer: A Case Series.
J Nucl Med. 2025 Feb 20:jnumed.124.268640. doi: 10.2967/jnumed.124.268640. PubMedAbstract available
KOSTOS L, Buteau JP, Kong G, Tran B, et al Clinical Trial Protocol for LuCAB: A Phase I-II Trial Evaluating Cabazitaxel in
Combination with [(177)Lu]Lu-PSMA-617 in Patients with Metastatic
Castration-Resistant Prostate Cancer.
J Nucl Med. 2025 Feb 20:jnumed.124.269252. doi: 10.2967/jnumed.124.269252. PubMedAbstract available
LINDENBERG L, Hope TA, Lin FI, Rowe SP, et al Safety, Dosimetry, and Feasibility of [(68)Ga]Ga-PSMA-R2 as an Imaging Agent in
Patients with Biochemical Recurrence or Metastatic Prostate Cancer.
J Nucl Med. 2025 Feb 6:jnumed.124.268318. doi: 10.2967/jnumed.124.268318. PubMedAbstract available
DERLIN T, Widjaja L, Harke NN, Czerner C, et al (99m)Tc-MIP-1404 SPECT/CT Companion Diagnostic for (177)Lu-PSMA Therapy in
Metastatic Castration-Resistant Prostate Cancer.
J Nucl Med. 2025 Feb 6:jnumed.124.269319. doi: 10.2967/jnumed.124.269319. PubMedAbstract available
VAN DER GAAG S, Vis AN, Bartelink IH, Koppes JCC, et al Exploring the Flare Phenomenon in Patients with Castration-Resistant Prostate
Cancer: Enzalutamide-Induced PSMA Upregulation Observed on PSMA PET.
J Nucl Med. 2025 Feb 6:jnumed.124.268340. doi: 10.2967/jnumed.124.268340. PubMedAbstract available
MORAITIS A, Kahl T, Kandziora J, Jentzen W, et al Evaluation of Surgical Margins with Intraoperative PSMA PET/CT and Their
Prognostic Value in Radical Prostatectomy.
J Nucl Med. 2025 Feb 6:jnumed.124.268719. doi: 10.2967/jnumed.124.268719. PubMedAbstract available
January 2025
LAWAL IO, Mushtaq A, Jani AB, Rupji M, et al Diuresis During (18)F-Flotufolastat (rhPSMA-7.3) PET/CT Improves Recurrence
Detection After Prostatectomy: A Prospective Phase II Trial.
J Nucl Med. 2025 Jan 23:jnumed.124.268574. doi: 10.2967/jnumed.124.268574. PubMedAbstract available
MADSEN C, Fuglo D, Pedersen M, Broholm R, et al Prospective Head-to-Head Comparison of (18)F-PSMA PET/CT and (18)F-NaF PET/CT for
Assessing Bone Metastases in 160 Patients with Newly Diagnosed High-Risk Prostate
Cancer.
J Nucl Med. 2025 Jan 8:jnumed.124.268275. doi: 10.2967/jnumed.124.268275. PubMedAbstract available
MILLER SR, Gonzalez RT, Jackson WC, Caram MEV, et al Rates of PSMA PET Staging and Positivity in Newly Diagnosed Prostate Cancer in a
National Health Care System.
J Nucl Med. 2025;66:75-83. PubMedAbstract available
UNTERRAINER LM, Hope TA, Fendler WP, Grogan T, et al Low- and High-Volume Disease in Metastatic Hormone-Sensitive Prostate Cancer:
From CHAARTED to PSMA PET-An International Multicenter Retrospective Study.
J Nucl Med. 2025;66:54-60. PubMedAbstract available
ZAID NRR, Bastiaannet R, Hobbs R, Sgouros G, et al Mathematic Modeling of Tumor Growth During [(177)Lu]Lu-PSMA Therapy: Insights
into Treatment Optimization.
J Nucl Med. 2025;66:84-90. PubMedAbstract available
SCHWEIGER L, Maurer T, Simon R, Horn T, et al Pattern of Failure in Patients with Biochemical Recurrence After PSMA Radioguided
Surgery.
J Nucl Med. 2025;66:67-72. PubMedAbstract available
November 2024
DEMIRCI RA, Ghodsi A, Gulati R, Behnia S, et al PET-Based TheraP Eligibility and Outcomes of VISION-Eligible Patients with
Metastatic Castration-Resistant Prostate Cancer Who Received (177)Lu-PSMA-617:
Importance of (18)F-FDG-Avid Discordant Findings.
J Nucl Med. 2024 Nov 14:jnumed.124.268167. doi: 10.2967/jnumed.124.268167. PubMedAbstract available
WENZEL M, Koll F, Hoeh B, Humke C, et al Real-World Comparison of Cabazitaxel Versus (177)Lu-PSMA Radiopharmaceutical
Therapy in Metastatic Castration-Resistant Prostate Cancer.
J Nucl Med. 2024 Nov 14:jnumed.124.268807. doi: 10.2967/jnumed.124.268807. PubMedAbstract available
DEMIRCI RA, Gulati R, Hawley JE, Yezefski T, et al SPECT/CT in Early Response Assessment of Patients with Metastatic
Castration-Resistant Prostate Cancer Receiving (177)Lu-PSMA-617.
J Nucl Med. 2024 Nov 7:jnumed.124.267665. doi: 10.2967/jnumed.124.267665. PubMedAbstract available
ZAGNI F, Vetrone L, Farolfi A, Vadala M, et al Feasibility of (177)Lu-PSMA Administration as Outpatient Procedure for Prostate
Cancer.
J Nucl Med. 2024 Nov 7:jnumed.124.268062. doi: 10.2967/jnumed.124.268062. PubMed
SAIDI A, Stallons TA, Wong AG, Torgue JJ, et al Preclinical Investigation of [(212)Pb]Pb-DOTAM-GRPR1 for Peptide Receptor
Radionuclide Therapy in a Prostate Tumor Model.
J Nucl Med. 2024;65:1769-1775. PubMedAbstract available
October 2024
SONNI I, Weiner AB, Doddipalli S, Deol M, et al Clinical, Pathologic, and Imaging Variables Associated with Prostate Cancer
Detection by PSMA PET/CT and Multiparametric MRI.
J Nucl Med. 2024 Oct 30:jnumed.124.268443. doi: 10.2967/jnumed.124.268443. PubMedAbstract available
HUANG RR, Zuo C, Mona CE, Holzgreve A, et al FAP and PSMA Expression by Immunohistochemistry and PET Imaging in
Castration-Resistant Prostate Cancer: A Translational Pilot Study.
J Nucl Med. 2024 Oct 30:jnumed.124.268037. doi: 10.2967/jnumed.124.268037. PubMedAbstract available
SWIHA M, Pathmanandavel S, Papa N, Sabahi Z, et al Comparison of Posttherapy 4- and 24-Hour [(177)Lu]Lu-PSMA SPECT/CT and Pretherapy
PSMA PET/CT in Assessment of Disease in Men with Metastatic Castration-Resistant
Prostate Cancer.
J Nucl Med. 2024 Oct 30:jnumed.124.267606. doi: 10.2967/jnumed.124.267606. PubMedAbstract available
MUNIZ M, Sartor O, Orme JJ, Koch RM, et al Outcomes for Patients with Metastatic Castration-Resistant Prostate Cancer and
Liver Metastasis Receiving [(177)Lu]Lu-PSMA-617.
J Nucl Med. 2024 Oct 30:jnumed.124.268277. doi: 10.2967/jnumed.124.268277. PubMedAbstract available
PISANO G, van Oosterom MN, Berrens AC, Slof LJ, et al Freehand SPECT Combined with 3-Dimensional Light Detection and Ranging as
Alternative Means of Specimen Scanning During Prostate Cancer Surgery.
J Nucl Med. 2024 Oct 3:jnumed.124.268256. doi: 10.2967/jnumed.124.268256. PubMed
CALAIS J, Morris MJ, Kendi AT, Kalebasty AR, et al Best Patient Care Practices for Administering PSMA-Targeted Radiopharmaceutical
Therapy.
J Nucl Med. 2024 Oct 3:jnumed.124.268363. doi: 10.2967/jnumed.124.268363. PubMedAbstract available
September 2024
MURTHY V, Voter AF, Nguyen K, Allen-Auerbach M, et al Efficacy and Toxicity of [(177)Lu]Lu-PSMA-617 for Metastatic Castration-Resistant
Prostate Cancer: Results from the U.S. Expanded-Access Program and Comparisons
with Phase 3 VISION Data.
J Nucl Med. 2024 Sep 26:jnumed.124.267816. doi: 10.2967/jnumed.124.267816. PubMedAbstract available
BERNARDINO RM, Lajkosz K, Yin LB, Sayyid RK, et al Association of Free-to-Total PSA Ratio and (18)F-DCFPyL Prostate-Specific
Membrane Antigen PET/CT Findings in Patients with Biochemical Recurrence After
Radical Prostatectomy: A Prospective Single-Center Study.
J Nucl Med. 2024 Sep 26:jnumed.124.267877. doi: 10.2967/jnumed.124.267877. PubMedAbstract available
POULIOT F, Saad F, Rousseau E, Richard PO, et al Intrapatient Intermetastatic Heterogeneity Determined by Triple-Tracer PET
Imaging in mCRPC Patients and Correlation to Survival: The 3TMPO Cohort Study.
J Nucl Med. 2024 Sep 26:jnumed.124.268020. doi: 10.2967/jnumed.124.268020. PubMedAbstract available
GAFITA A, Voter A, Shesadri S, Spitz A, et al Initial Experience with [(177)Lu]Lu-PSMA-617 After Regulatory Approval for
Metastatic Castration-Resistant Prostate Cancer: Efficacy, Safety, and Outcome
Prediction.
J Nucl Med. 2024 Sep 19:jnumed.124.267723. doi: 10.2967/jnumed.124.267723. PubMedAbstract available
BAUCKNEHT M, D'Amico F, Albano D, Balma M, et al Composite Prediction Score to Interpret Bone Focal Uptake in Hormone-Sensitive
Prostate Cancer Patients Imaged with [(18)F]PSMA-1007 PET/CT.
J Nucl Med. 2024 Sep 5:jnumed.124.267751. doi: 10.2967/jnumed.124.267751. PubMedAbstract available
POSCHENRIEDER A, Taleska J, Schaetz L (177)Lu-PSMA (R)Evolution in Cancer Care: Is It Really Happening?
J Nucl Med. 2024;65:1340-1342. PubMed
BELGE BILGIN G, Burkett BJ, Bilgin C, Orme JJ, et al Neurologic Symptoms After (177)Lu-Prostate-Specific-Membrane Antigen-617 Therapy:
A Single-Center Experience.
J Nucl Med. 2024;65:1402-1408. PubMedAbstract available
August 2024
WONG AJN, Ko HS, Hofman MS Navigating the Future of Prostate Cancer Care: AI-Driven Imaging and Theranostics
Through the Lens of RELAINCE.
J Nucl Med. 2024 Aug 29:jnumed.124.267924. doi: 10.2967/jnumed.124.267924. PubMed
THIN P, Hotta M, Gafita A, Grogan T, et al Clinical Factors That Influence Repeat (68)Ga-PSMA-11 PET/CT Scan Positivity in
Patients with Recurrent Prostate Cancer Under Observation After a Negative
(68)Ga-PSMA-11 PET/CT Scan: A Single-Center Retrospective Study.
J Nucl Med. 2024 Aug 21:jnumed.124.267591. doi: 10.2967/jnumed.124.267591. PubMedAbstract available
HO KV, Tatum DS, Watkinson L, Carmack T, et al Single Chelator-Minibody Theranostic Agents for (89)Zr PET Imaging and (177)Lu
Radiopharmaceutical Therapy of PSMA-Expressing Prostate Cancer.
J Nucl Med. 2024 Aug 14:jnumed.124.267667. doi: 10.2967/jnumed.124.267667. PubMedAbstract available
MAINTA IC, Neroladaki A, Wolf NB, Benamran D, et al [(68)Ga]Ga-PSMA-11 PET and Prostate Cancer Bone Metastases: Diagnostic
Performance of Available Standardized Criteria.
J Nucl Med. 2024 Aug 8:jnumed.124.267899. doi: 10.2967/jnumed.124.267899. PubMedAbstract available
YADAV S, Lowery B, Tuchayi AM, Jiang F, et al Impact of Posttreatment SPECT/CT on Patient Management During (177)Lu-PSMA-617
Radiopharmaceutical Therapy.
J Nucl Med. 2024 Aug 8:jnumed.124.267955. doi: 10.2967/jnumed.124.267955. PubMedAbstract available
OSMAN MM, Iravani A, Mitchell C, Hicks RJ, et al (18)F-DCFPyL PSMA PET/CT Tracheobronchial Uptake in Patients with Prostate
Cancer: Incidence and Etiology.
J Nucl Med. 2024 Aug 1:jnumed.124.267772. doi: 10.2967/jnumed.124.267772. PubMedAbstract available
LI S, Nguyen A, Counter W, John NC, et al Utility of (64)Cu-Sarcophagine-Bombesin PET/CT in Men with Biochemically
Recurrent Prostate Cancer and Negative or Equivocal Findings on (68)Ga-PSMA-11
PET/CT.
J Nucl Med. 2024 Aug 1:jnumed.124.267881. doi: 10.2967/jnumed.124.267881. PubMedAbstract available
NIKITAS J, Castellanos Rieger A, Farolfi A, Seyedroudbari A, et al Prostate-Specific Membrane Antigen PET/CT-Guided, Metastasis-Directed
Radiotherapy for Oligometastatic Castration-Resistant Prostate Cancer.
J Nucl Med. 2024 Aug 1:jnumed.124.267922. doi: 10.2967/jnumed.124.267922. PubMedAbstract available
ANGAPPULIGE DH, Barashi NS, Pickersgill N, Weimholt C, et al Prostate-Specific Membrane Antigen-Targeted Imaging and Its Correlation with
HOXB13 Expression.
J Nucl Med. 2024;65:1210-1216. PubMedAbstract available
July 2024
DUIN JJ, de Barros HA, van Leeuwen PJ, van der Poel HG, et al Reply: Considerations Surrounding the Sentinel Lymph Node in Prostate Cancer and
Unanswered Questions.
J Nucl Med. 2024 Jul 25:jnumed.124.267658. doi: 10.2967/jnumed.124.267658. PubMed
AH-THIANE L, Ferrer L, Supiot S, Rousseau C, et al Considerations Surrounding the Sentinel Lymph Node in Prostate Cancer and
Unanswered Questions.
J Nucl Med. 2024 Jul 25:jnumed.124.267477. doi: 10.2967/jnumed.124.267477. PubMed
BASACO BERNABEU T, Mansi R, Del Pozzo L, Zanger S, et al (61)Cu-PSMA-Targeted PET for Prostate Cancer: From Radiotracer Development to
First-in-Human Imaging.
J Nucl Med. 2024 Jul 18:jnumed.123.267126. doi: 10.2967/jnumed.123.267126. PubMedAbstract available
BUTEAU JP, Kostos L, Alipour R, Jackson P, et al Clinical Trial Protocol for VIOLET: A Single-Center, Phase I/II Trial Evaluation
of Radioligand Treatment in Patients with Metastatic Castration-Resistant
Prostate Cancer with [(161)Tb]Tb-PSMA-I&T.
J Nucl Med. 2024 Jul 11:jnumed.124.267650. doi: 10.2967/jnumed.124.267650. PubMedAbstract available
ELLS Z, Grogan TR, Czernin J, Dahlbom M, et al Dosimetry of [(177)Lu]Lu-PSMA-Targeted Radiopharmaceutical Therapies in Patients
with Prostate Cancer: A Comparative Systematic Review and Metaanalysis.
J Nucl Med. 2024 Jul 3:jnumed.124.267452. doi: 10.2967/jnumed.124.267452. PubMedAbstract available
RATHKE H, Winter E, Bruchertseifer F, Rohrich M, et al Deescalated (225)Ac-PSMA-617 Versus (177)Lu/(225)Ac-PSMA-617 Cocktail Therapy: A
Single-Center Retrospective Analysis of 233 Patients.
J Nucl Med. 2024;65:1057-1063. PubMedAbstract available
June 2024
BAUCKNEHT M, Lanfranchi F, Albano D, Triggiani L, et al Diverse Imaging Methods May Influence Long-Term Oncologic Outcomes in
Oligorecurrent Prostate Cancer Patients Treated with Metastasis-Directed Therapy
(the PRECISE-MDT Study).
J Nucl Med. 2024 Jun 27:jnumed.124.267586. doi: 10.2967/jnumed.124.267586. PubMedAbstract available
KUO PH, Esposito G, Ulaner GA, Yoo D, et al Interreader and Intrareader Reproducibility of (18)F-Flotufolastat Image
Interpretation in Patients with Newly Diagnosed or Recurrent Prostate Cancer:
Data from Two Phase 3 Prospective Multicenter Studies.
J Nucl Med. 2024 Jun 13:jnumed.123.267306. doi: 10.2967/jnumed.123.267306. PubMedAbstract available
EVANGELISTA L, Zattoni F, Burei M, Bertin D, et al A Prospective Randomized Multicenter Study on the Impact of [(18)F]F-Choline
PET/CT Versus Conventional Imaging for Staging Intermediate- to High-Risk
Prostate Cancer.
J Nucl Med. 2024 Jun 6:jnumed.123.267355. doi: 10.2967/jnumed.123.267355. PubMedAbstract available
PHAM TT, Hungnes IN, Rivas C, Cleaver J, et al Receptor-Targeted Peptide Conjugates Based on Diphosphines Enable Preparation of
(99m)Tc and (188)Re Theranostic Agents for Prostate Cancer.
J Nucl Med. 2024 Jun 6:jnumed.124.267450. doi: 10.2967/jnumed.124.267450. PubMedAbstract available
SEIFERT R, Telli T, Lapa C, Desaulniers M, et al Safety and Efficacy of Extended Therapy with [(177)Lu]Lu-PSMA: A German
Multicenter Study.
J Nucl Med. 2024;65:909-916. PubMedAbstract available
May 2024
PANDIT-TASKAR N, O'Donoghue JA, Chetty D, Max S, et al A Phase 0 Study to Assess the Biodistribution and Pharmacokinetics of a
Radiolabeled Antibody Targeting Human Kallikrein 2 in Participants with
Metastatic Castration-Resistant Prostate Cancer.
J Nucl Med. 2024 May 23:jnumed.124.267416. doi: 10.2967/jnumed.124.267416. PubMedAbstract available
IMBERTI C, De Gregorio R, Korsen JA, Hoang TT, et al CEACAM5-Targeted Immuno-PET in Androgen Receptor-Negative Prostate Cancer.
J Nucl Med. 2024 May 23:jnumed.123.267107. doi: 10.2967/jnumed.123.267107. PubMedAbstract available
FLEMING MT, Hermsen R, Purysko AS, Chau A, et al True-Positive (18)F-Flotufolastat Lesions in Patients with Prostate Cancer
Recurrence with Baseline-Negative Conventional Imaging: Results from the
Prospective, Phase 3, Multicenter SPOTLIGHT Study.
J Nucl Med. 2024 May 23:jnumed.123.267271. doi: 10.2967/jnumed.123.267271. PubMedAbstract available
ZANG J, Yang Y, Chen S, Wang C, et al Diagnostic Performance of [(18)F]AlF-Thretide PET/CT in Patients with Newly
Diagnosed Prostate Cancer Using Histopathology as Reference Standard.
J Nucl Med. 2024 May 9:jnumed.123.266940. doi: 10.2967/jnumed.123.266940. PubMedAbstract available
YADAV S, Jiang F, Kurkowska S, Saelee R, et al Assessing Response to PSMA Radiopharmaceutical Therapies with Single SPECT
Imaging at 24 Hours After Injection.
J Nucl Med. 2024 May 9:jnumed.123.267208. doi: 10.2967/jnumed.123.267208. PubMedAbstract available
MORADI TUCHAYI A, Yadav S, Jiang F, Kim ST, et al Real-World Experience with (177)Lu-PSMA-617 Radioligand Therapy After Food and
Drug Administration Approval.
J Nucl Med. 2024;65:735-739. PubMedAbstract available
April 2024
NIKITAS J, Lam E, Booker KA, Fendler WP, et al Randomized Trial of Prostate-Specific Membrane Antigen PET/CT Before Definitive
Radiotherapy for Unfavorable Intermediate- and High-Risk Prostate Cancer
(PSMA-dRT Trial).
J Nucl Med. 2024 Apr 25:jnumed.123.267004. doi: 10.2967/jnumed.123.267004. PubMedAbstract available
DUAN H, Song H, Davidzon GA, Moradi F, et al Prospective Comparison of (68)Ga-NeoB and (68)Ga-PSMA-R2 PET/MRI in Patients with
Biochemically Recurrent Prostate Cancer.
J Nucl Med. 2024 Apr 25:jnumed.123.267017. doi: 10.2967/jnumed.123.267017. PubMedAbstract available
GAFITA A, Djaileb L, Rauscher I, Fendler WP, et al RECIP 1.0 Predicts Progression-Free Survival After [(177)Lu]Lu-PSMA
Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant
Prostate Cancer.
J Nucl Med. 2024 Apr 18:jnumed.123.267234. doi: 10.2967/jnumed.123.267234. PubMedAbstract available
HUANG YY, Lin TC, Yang SH, Lai LS, et al [(177)Lu]Lu-Prostate-Specific Membrane Antigen-617 in a Patient with Metastatic
Castration-Resistant Prostate Cancer and Status After Bilateral Nephrectomy.
J Nucl Med. 2024 Apr 18:jnumed.124.267533. doi: 10.2967/jnumed.124.267533. PubMed
SWIHA M, Papa N, Sabahi Z, Ayati N, et al Development of a Visually Calculated SUV(mean) (HIT Score) on Screening PSMA
PET/CT to Predict Treatment Response to (177)Lu-PSMA Therapy: Comparison with
Quantitative SUV(mean) and Patient Outcomes.
J Nucl Med. 2024 Apr 18:jnumed.123.267014. doi: 10.2967/jnumed.123.267014. PubMedAbstract available
VISCUSE P, Devitt M, Dreicer R Clinical Management of Advanced Prostate Cancer: Where Does Radiopharmaceutical
Therapy Fit in the Treatment Algorithm?
J Nucl Med. 2024 Apr 11:jnumed.123.267006. doi: 10.2967/jnumed.123.267006. PubMedAbstract available
BAUCKNEHT M, Fornarini G, Di Raimondo T, Pardini M, et al Brain Metabolic Correlates of the Off-Target Effects of Enzalutamide on the
Central Nervous System of Patients with Advanced Prostate Cancer.
J Nucl Med. 2024 Apr 11:jnumed.124.267526. doi: 10.2967/jnumed.124.267526. PubMed
HARDIANSYAH D, Yousefzadeh-Nowshahr E, Kind F, Beer AJ, et al Single-Time-Point Renal Dosimetry Using Nonlinear Mixed-Effects Modeling and
Population-Based Model Selection in [(177)Lu]Lu-PSMA-617 Therapy.
J Nucl Med. 2024;65:566-572. PubMedAbstract available
March 2024
BERRENS AC, Sorbi MA, Donswijk ML, de Barros HA, et al Strong Correlation Between SUV(max) on PSMA PET/CT and Numeric Drop-In gamma-Probe
Signal for Intraoperative Identification of Prostate Cancer Lesions.
J Nucl Med. 2024 Mar 14:jnumed.123.267075. doi: 10.2967/jnumed.123.267075. PubMedAbstract available
SHI J, Li D, Chen M, Fu Y, et al The Value of (68)Ga-PSMA PET/MRI for Classifying Patients with PI-RADS 3 Lesions
on Multiparametric MRI: A Prospective Single-Center Study.
J Nucl Med. 2024 Mar 14:jnumed.123.266742. doi: 10.2967/jnumed.123.266742. PubMedAbstract available
HARTRAMPF PE, Huttmann T, Seitz AK, Kubler H, et al Prognostic Performance of RECIP 1.0 Based on [(18)F]PSMA-1007 PET in Prostate
Cancer Patients Treated with [(177)Lu]Lu-PSMA I&T.
J Nucl Med. 2024 Mar 7:jnumed.123.266702. doi: 10.2967/jnumed.123.266702. PubMedAbstract available
February 2024
EL FAKIRI M, Ayada N, Muller M, Hvass L, et al Development and Preclinical Evaluation of [(211)At]PSAt-3-Ga: An Inhibitor for
Targeted alpha-Therapy of Prostate Cancer.
J Nucl Med. 2024 Feb 29:jnumed.123.267043. doi: 10.2967/jnumed.123.267043. PubMedAbstract available
GRIFFITHS MR, Pattison DA, Latter M, Kuan K, et al First-in-Human (212)Pb-PSMA-Targeted alpha-Therapy SPECT/CT Imaging in a Patient with
Metastatic Castration-Resistant Prostate Cancer.
J Nucl Med. 2024 Feb 29:jnumed.123.267189. doi: 10.2967/jnumed.123.267189. PubMed
BOSCH D, van der Velden KJM, Oving IM, Wyndaele DNJ, et al The Impact of Baseline PSMA PET/CT Versus CT on Outcomes of (223)Ra Therapy in
Metastatic Castration-Resistant Prostate Cancer Patients.
J Nucl Med. 2024 Feb 29:jnumed.123.266654. doi: 10.2967/jnumed.123.266654. PubMedAbstract available
LEUNG KH, Rowe SP, Sadaghiani MS, Leal JP, et al Deep Semisupervised Transfer Learning for Fully Automated Whole-Body Tumor
Quantification and Prognosis of Cancer on PET/CT.
J Nucl Med. 2024 Feb 29:jnumed.123.267048. doi: 10.2967/jnumed.123.267048. PubMedAbstract available
MAURER T, Thomas C, Hadaschik B The DETECT Trial: Are We on the Verge of Precision Surgery in Primary Prostate
Cancer?
J Nucl Med. 2024 Feb 15:jnumed.123.267187. doi: 10.2967/jnumed.123.267187. PubMed
KUMAR S, Crumbaker M, Emmett L Reply: Unraveling the Hypocalcemic Response to (177)Lu-Prostate-Specific Membrane
Antigen Therapy.
J Nucl Med. 2024;65:333-334. PubMed
ASKARI E, Harsini S Unraveling the Hypocalcemic Response to (177)Lu-Prostate-Specific Membrane
Antigen Therapy.
J Nucl Med. 2024;65:332-333. PubMed
January 2024
LIGHT A, Lazic S, Houghton K, Bayne M, et al Diagnostic Performance of (68)Ga-PSMA-11 PET/CT Versus Multiparametric MRI for
Detection of Intraprostatic Radiorecurrent Prostate Cancer.
J Nucl Med. 2024 Jan 11:jnumed.123.266527. doi: 10.2967/jnumed.123.266527. PubMedAbstract available
SCHILHAM MGM, Somford DM, Kusters-Vandevelde HVN, Hermsen R, et al Prostate-Specific Membrane Antigen-Targeted Radioguided Pelvic Lymph Node
Dissection in Newly Diagnosed Prostate Cancer Patients with a Suspicion of
Locoregional Lymph Node Metastases: The DETECT Trial.
J Nucl Med. 2024 Jan 4:jnumed.123.266495. doi: 10.2967/jnumed.123.266495. PubMedAbstract available
RAHBAR K, Boegemann M The Imperative for Comparative Studies in Nuclear Medicine: Elevating
(177)Lu-PSMA-617 in the Treatment Paradigm for mCRPC.
J Nucl Med. 2024 Jan 4:jnumed.123.266952. doi: 10.2967/jnumed.123.266952. PubMed
UNTERRAINER LM, Ruchalski K, Allen-Auerbach MS, Calais J, et al PSMA PET/CT Dual-Time-Point Imaging: Nice to Have or Need to Have?
J Nucl Med. 2024 Jan 4:jnumed.123.266722. doi: 10.2967/jnumed.123.266722. PubMed
RAVI KUMAR AS, Hofman MS Unraveling the Impact of (177)Lu-PSMA Radioligand Therapy on Renal Impairment:
Distinguishing Causation from Correlation.
J Nucl Med. 2024;65:85-86. PubMed
STEINHELFER L, Lunger L, Cala L, Pfob CH, et al Long-Term Nephrotoxicity of (177)Lu-PSMA Radioligand Therapy.
J Nucl Med. 2024;65:79-84. PubMedAbstract available
December 2023
DIERKS A, Gable A, Rinscheid A, Wienand G, et al First Safety and Efficacy Data with the Radiohybrid (177)Lu-rhPSMA-10.1 for the
Treatment of Metastatic Prostate Cancer.
J Nucl Med. 2023 Dec 21:jnumed.123.266741. doi: 10.2967/jnumed.123.266741. PubMedAbstract available
BENABDALLAH N, Lu P, Abou DS, Zhang H, et al Beyond Average: alpha-Particle Distribution and Dose Heterogeneity in Bone Metastatic
Prostate Cancer.
J Nucl Med. 2023 Dec 14:jnumed.123.266571. doi: 10.2967/jnumed.123.266571. PubMedAbstract available
JADVAR H Sequential and Combination Therapies of (223)RaCl(2) and Prostate-Specific
Membrane Antigen Radioligand Therapy.
J Nucl Med. 2023;64:1932-1933. PubMed
November 2023
EMMETT L, Papa N, Counter W, Calais J, et al Reproducibility and Accuracy of the PRIMARY Score on PSMA PET and of PI-RADS on
Multiparametric MRI for Prostate Cancer Diagnosis Within a Real-World Database.
J Nucl Med. 2023 Nov 30:jnumed.123.266164. doi: 10.2967/jnumed.123.266164. PubMedAbstract available
WANG F, Liu C, Vidal I, Mana-Ay M, et al Comparison of Multiple Segmentation Methods for Volumetric Delineation of Primary
Prostate Cancer with Prostate-Specific Membrane Antigen-Targeted (18)F-DCFPyL
PET/CT.
J Nucl Med. 2023 Nov 30:jnumed.123.266005. doi: 10.2967/jnumed.123.266005. PubMedAbstract available
KLUGE K, Einspieler H, Haberl D, Spielvogel C, et al Examining the Relationship and Prognostic Significance of Cell-Free DNA Levels
and the PSMA-Positive Tumor Volume in Men with Prostate Cancer: A
Retrospective-Prospective [(68)Ga]Ga-PSMA-11 PET/CT Study.
J Nucl Med. 2023 Nov 30:jnumed.123.266158. doi: 10.2967/jnumed.123.266158. PubMedAbstract available
HERRMANN K, Rahbar K, Eiber M, Sparks R, et al Renal and Multiorgan Safety of (177)Lu-PSMA-617 in Patients with Metastatic
Castration-Resistant Prostate Cancer in the VISION Dosimetry Substudy.
J Nucl Med. 2023 Nov 30:jnumed.123.265448. doi: 10.2967/jnumed.123.265448. PubMedAbstract available
SARTOR O, Ledet E, Huang M, Schwartz J, et al Prediction of Resistance to (177)Lu-PSMA Therapy by Assessment of Baseline
Circulating Tumor DNA Biomarkers.
J Nucl Med. 2023;64:1721-1725. PubMedAbstract available
October 2023
RAHBAR K, Essler M, Eiber M, la Fougere C, et al (177)Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic
Castration-Resistant Prostate Cancer and Prior (223)Ra (RALU Study).
J Nucl Med. 2023 Oct 12:jnumed.123.266125. doi: 10.2967/jnumed.123.266125. PubMedAbstract available
MEYER C, Stuparu A, Lueckerath K, Calais J, et al Tandem Isotope Therapy with (225)Ac- and (177)Lu-PSMA-617 in a Murine Model of
Prostate Cancer.
J Nucl Med. 2023 Oct 5:jnumed.123.265433. doi: 10.2967/jnumed.123.265433. PubMedAbstract available
TSCHAN VJ, Busslinger SD, Bernhardt P, Grundler PV, et al Albumin-Binding and Conventional PSMA Ligands in Combination with (161)Tb:
Biodistribution, Dosimetry, and Preclinical Therapy.
J Nucl Med. 2023;64:1625-1631. PubMedAbstract available
MELLHAMMAR E, Dahlbom M, Vilhelmsson-Timmermand O, Strand SE, et al Tumor Control Probability and Small-Scale Monte Carlo Dosimetry: Effects of
Heterogenous Intratumoral Activity Distribution in Radiopharmaceutical Therapy.
J Nucl Med. 2023;64:1632-1637. PubMedAbstract available
GRAVES SA Radiation Safety Considerations of Household Waste Disposal After Release of
Patients Who Have Received [(177)Lu]Lu-PSMA-617.
J Nucl Med. 2023;64:1567-1569. PubMedAbstract available
September 2023
SHAGERA QA, Karfis I, Kristanto P, Spyridon S, et al PSMA PET/CT for Response Assessment and Overall Survival Prediction in Patients
with Metastatic Castration-Resistant Prostate Cancer Treated with Androgen
Receptor Pathway Inhibitors.
J Nucl Med. 2023 Sep 28:jnumed.123.265874. doi: 10.2967/jnumed.123.265874. PubMedAbstract available
RINSCHEID A, Gable A, Wienand G, Pfob C, et al An Intrapatient Dosimetry Comparison of (177)Lu-rhPSMA-10.1 and (177)Lu-PSMA-I&T
in Patients with Metastatic Castration-Resistant Prostate Cancer.
J Nucl Med. 2023 Sep 28:jnumed.123.265970. doi: 10.2967/jnumed.123.265970. PubMedAbstract available
KLUGE K, Haberl D, Einspieler H, Rasul S, et al Antihormonal-Treatment Status Affects (68)Ga-PSMA-HBED-CC PET Biodistribution in
Patients with Prostate Cancer.
J Nucl Med. 2023 Sep 21:jnumed.123.265980. doi: 10.2967/jnumed.123.265980. PubMedAbstract available
SATAPATHY S, Mittal BR, Sood A, Das CK, et al [(177)Lu]Lu-PSMA-617 Versus Docetaxel in Chemotherapy-Naive Metastatic
Castration-Resistant Prostate Cancer: Final Survival Analysis of a Phase 2
Randomized, Controlled Trial.
J Nucl Med. 2023 Sep 14:jnumed.123.266141. doi: 10.2967/jnumed.123.266141. PubMedAbstract available
KARIMZADEH A, Soeiro P, Feuerecker B, Hecker CS, et al Improved Quality of Life in Metastatic Castration-Resistant Prostate Cancer
Patients Receiving Consecutive Cycles of (177)Lu-PSMA I&T.
J Nucl Med. 2023 Sep 7:jnumed.123.265878. doi: 10.2967/jnumed.123.265878. PubMedAbstract available
MURTHY V, Gafita A, Thin P, Nguyen K, et al Prognostic Value of End-of-Treatment PSMA PET/CT in Patients Treated with
(177)Lu-PSMA Radioligand Therapy: A Retrospective, Single-Center Analysis.
J Nucl Med. 2023 Sep 7:jnumed.122.265155. doi: 10.2967/jnumed.122.265155. PubMedAbstract available
KUMAR S, Crumbaker M, Harvey C, Pathmanandavel S, et al The Tyr Phenomenon: A Hypocalcemic Response in High-Volume Treatment Responders
to (177)Lu-Prostate-Specific Membrane Antigen Therapy.
J Nucl Med. 2023;64:1412-1416. PubMedAbstract available
MURTHY V, Allen-Auerbach M, Lam R, Owen D, et al PSMA-Negative Lesion Progression Under (177)Lu-PSMA Radioligand Therapy.
J Nucl Med. 2023;64:1502-1503. PubMed
HOPE TA, Antonarakis ES, Bodei L, Calais J, et al SNMMI Consensus Statement on Patient Selection and Appropriate Use of
(177)Lu-PSMA-617 Radionuclide Therapy.
J Nucl Med. 2023;64:1417-1423. PubMed
August 2023
VAN LITH SAM, Pruis IJ, Tolboom N, Snijders TJ, et al PET Imaging and Protein Expression of Prostate-Specific Membrane Antigen in
Glioblastoma: A Multicenter Inventory Study.
J Nucl Med. 2023 Aug 31:jnumed.123.265738. doi: 10.2967/jnumed.123.265738. PubMedAbstract available
HOHBERG M, Reifegerst M, Drzezga A, Wild M, et al Prediction of Response to (177)Lu-PSMA Therapy Based on Tumor-to-Kidney Ratio on
Pretherapeutic PSMA PET/CT and Posttherapeutic Tumor-Dose Evaluation in mCRPC.
J Nucl Med. 2023 Aug 31:jnumed.122.264953. doi: 10.2967/jnumed.122.264953. PubMedAbstract available
HOPE TA, Benz M, Jiang F, Thompson D, et al Do Bone Scans Overstage Disease Compared with PSMA PET at Initial Staging? An
International Multicenter Retrospective Study with Masked Independent Readers.
J Nucl Med. 2023 Aug 17:jnumed.123.265916. doi: 10.2967/jnumed.123.265916. PubMedAbstract available
July 2023
MELLHAMMAR E, Dahlbom M, Vilhelmsson-Timmermand O, Strand SE, et al Tumor Control Probability and Small-Scale Monte Carlo Dosimetry: Effects of
Heterogenous Intratumoral Activity Distribution in Radiopharmaceutical Therapy.
J Nucl Med. 2023 Jul 27:jnumed.123.265523. doi: 10.2967/jnumed.123.265523. PubMedAbstract available
KOLLER L, Joksch M, Schwarzenbock S, Kurth J, et al Preclinical Comparison of the (64)Cu- and (68)Ga-Labeled GRPR-Targeted Compounds
RM2 and AMTG, as Well as First-in-Humans [(68)Ga]Ga-AMTG PET/CT.
J Nucl Med. 2023 Jul 20:jnumed.123.265771. doi: 10.2967/jnumed.123.265771. PubMedAbstract available
STRAUB M, Kupferschlager J, Serna Higuita LM, Weissinger M, et al Dual-Time-Point Posttherapy (177)Lu-PSMA-617 SPECT/CT Describes the Uptake
Kinetics of mCRPC Lesions and Prognosticates Patients' Outcome.
J Nucl Med. 2023 Jul 6:jnumed.122.264770. doi: 10.2967/jnumed.122.264770. PubMedAbstract available